Immunotherapy for Alzheimer's disease (Q57419087)

Peter Henry St George-Hyslop

Europe PubMed Central

title

Immunotherapy for Alzheimer's disease (English)

0 references

1 reference

1 reference

object named as

Peter St George-Hyslop

4

0 references

author name string

David S Gelinas

1

0 references

Kevin DaSilva

2

0 references

Daniela Fenili

3

0 references

Joanne McLaurin

Proceedings of the National Academy of Sciences of the United States of America

5

0 references

language of work or name

English

0 references

publication date

5 October 2004

0 references

published in

0 references

volume

101 Suppl 2

0 references

page(s)

14657-62

0 references

issue

Supplement 2

0 references

cites work

Alzheimer's disease: treatments in discovery and development

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Review: modulating factors in amyloid-beta fibril formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

The toxicity in vitro of beta-amyloid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Some morphometric aspects of the brain in senile dementia of the alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Correlations of synaptic and pathological markers with cognition of the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Cerebral hemorrhage after passive anti-Abeta immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Pubertal changes in biochemical markers of growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Inflammation and therapeutic vaccination in CNS diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Immunization with beta-amyloid: could T-cell activation have a harmful effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Inflammation and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

New gene-based approaches for an AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Cancer vaccines: between the idea and the reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Degradation of beta-amyloid by proteolytic antibody light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Microparticles and Nanoparticles as Delivery Systems for DNA Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0404866101

Cocaine use may damage dopaminergic system

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521991

Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521991

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521991

Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521991

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521991

Alzheimer's disease: genes, proteins, and therapy

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521991

Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521991

Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521991

Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521991

In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521991

A$beta;1-15 is less immunogenic than A$beta;1-40/42 for intranasal immunization of wild-type mice but may be effective for ?boosting?

2 November 2018

1 reference

12 December 2020

Dosing in phase II trial of Alzheimer's vaccine suspended

1 reference

12 December 2020

Immunotherapy for Alzheimer's disease

1 reference

12 December 2020

Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Th1 cells

1 reference

12 December 2020

Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice

1 reference

12 December 2020